Four years ago, KING 5 shared Milton Wright's story after he had completed immunotherapy treatment at Seattle Children's. Milton was the second patient to beat leukemia with T-cell immunotherapy, and after nearly 12 years of battling cancer, it's easy to understand why he would shy away from the medical setting.
STRIvE-01, a trial underway at Seattle Children's, will evaluate chimeric antigen receptor T-cell therapy for children and young adults with relapsed or refractory noncentral nervous system EGFR-expressing solid tumors.
Harper Beare, just shy of her second birthday, has spent nearly half her life in and out of hospitals after being diagnosed with leukemia. After four rounds of chemotherapy didn't put Harper into remission, her doctor recommended an immunotherapy trial at Seattle Children's.
Just as Seattle Children's Hospital has initiated a study of two CAR-T cell therapies in young people with relapsed or refractory non-central nervous system epidermal growth factor receptor (EGFR)-positive solid tumors, GlobalData states that if study data are positive, collaboration with industry will be required to support further clinical development and commercialization.